Zydus-Sunshine JV signs agreement with Board of Investment, Sri Lanka to set up pharma facility
Zydus Sunshine Lifesciences (Pvt) Ltd, the proposed JV of Zydus and Sunshine Healthcare, signed an agreement with the Board of Investment of Sri Lanka on 13 October 2026 to set up a pharma facility in Horana.
By ScoutQuest · · 1 min read
- Investment
- Phased investment over USD 20 million
- Operations Timeline
- Operations expected in 2028
- Facility Site
- Nearly four acres in the BOI zone in Horana, Sri Lanka
What was announced
- Zydus Sunshine Lifesciences (Pvt) Ltd, the proposed joint venture between Zydus Lifesciences Limited and Sunshine Healthcare (part of Sunshine Holdings PLC), has signed an agreement with the Board of Investment of Sri Lanka on 13 October 2026.
- The agreement is to establish a pharmaceutical manufacturing facility in the BOI zone in Horana, Sri Lanka.
- The two companies had announced the formation of the joint venture on 26 June 2026.
The investment
- The project envisages a phased investment of over USD 20 million.
- The facility will be developed on a site of nearly four acres.
- Commercial operations are expected to commence in 2028, subject to project timelines and relevant regulatory approvals.
What the plant will make
- In its first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market.
- The investment is described as supporting Zydus' international presence and its commitment to expanding access to quality medicines.
- Local manufacturing is expected to strengthen medicine supply chain resilience and support the availability of essential medicines in Sri Lanka.
How to read this
- This is an agreement signed by the proposed joint venture to set up a manufacturing facility; commercial operations are expected to commence in 2028, subject to project timelines and relevant regulatory approvals.
- The investment is phased, and the first phase is aimed at the Sri Lankan market.
- The commitment is over USD 20 million, spread across phases as the project progresses.
Also from Zydus Lifesciences
Zydus Lifesciences Q2 FY27 results on Nov 4, 2026; post-results earnings call same day at 3:30 p.m. IST
24 Oct 2026
Zylidac Bio and Prolific Machines partner to scale Prolific's light-controlled biologics platform to GMP production
21 Oct 2026
Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity
21 Oct 2026
More numbers
- Phased investment envisaged for the projectover USD 20 million
- Site area for the facilitynearly four acres
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.